ViiV Healthcare Presents New Data from HIV/AIDS Portfolio Demonstrating Research Advances and Commitment to Patient Care at Conference on Retroviruses and Opportunistic Infections

Presentations Include New Data for S/GSK1349572, an Integrase Inhibitor in Clinical Development, SELZENTRY(R), and EPZICOM(R)

SAN FRANCISCO, February 22, 2010 - At the 17th Conference on Retroviruses and Opportunistic Infections
(CROI), ViiV Healthcare presented new data across its broad range of
investigational and current medicines for the treatment of HIV/AIDS.
Highlighted data at the conference included an oral presentation on the
investigational integrase inhibitor, S/GSK1349572, as well as data
presentations on SELZENTRY(R) (maraviroc) and EPZICOM(R)
(abacavir/lamivudine).

"ViiV Healthcare is dedicated to the pursuit of new scientific insights
that could help solve complex treatment issues for HIV. We hope that our
findings on both our investigational compounds and our available medicines
will further enable treatments to be better tailored to the individual
patient," stated Dr. Dominique Limet, chief executive officer of ViiV
Healthcare. "Beyond currently available therapies, there remains a
substantial need for new and effective treatment options. We are committed to
advancing S/GSK1349572, as integrase inhibitors represent an important new
class of medications for treating patients with HIV."

Overall, more than 24 abstracts were presented during the conference
relating to ViiV Healthcare's current medicines and pipeline. These
presentations underscore the company's commitment to enhancing its knowledge
base for its current medicines, tackling major challenges in treating
HIV/AIDS, and providing patients and physicians with data that can lead to
more informed prescribing decisions. Highlights from the presentations on
S/GSK1349572, SELZENTRY, and EPZICOM are described below.

Data Presentations on S/GSK1349572

An oral presentation described the innovative and rational design
approach that led to the identification of a potent series of HIV-1 integrase
inhibitors, including the lead clinical candidate, S/GSK1349572. In vitro
studies of S/GSK1349572 across a range of subtypes suggest that S/GSK1349572
displays potent antiviral activity to wild type-virus and key integrase
inhibitor-resistant HIV. S/GSK1349572 was additive or synergistic, with no
observed antagonism of antiviral activity with approved drugs from all
classes. The preclinical attributes were confirmed in a Phase IIa study
during which HIV-infected subjects receiving S/GSK1349572 50mg alone once
daily for 10 days had a mean reduction in HIV-1 of 2.5 log10 c/mL.

In vitro data presented on the resistance profile of S/GSK1349572 suggest
that S/GSK1349572 demonstrates activity against site-directed molecular
clones generated primarily based on raltegravir (RAL) and elvitegravir (ELV)
resistant viruses observed in clinical trials. These data suggest that
S/GSK1349572 has a resistance profile distinct from raltegravir and
elvitegravir. ViiV Healthcare continues to characterize the resistance
profile of S/GSK1349572 in clinical studies.

Additionally, data from a Phase I study suggest that S/GSK1349572
administered in combination with atazanavir (ATV) or ATV/ritonavir (RTV)
results in S/GSK1349572 exposure levels that do not require dose adjustment
and was generally well tolerated in healthy adult subjects. No clinically
significant trends in laboratory values, vital signs, or electrocardiograms
(ECGs) were observed during study drug dosing. All adverse events (AEs) were
mild or moderate, and no subject withdrew from the study due to an AE. The
most common drug related AE observed during treatment with S/GSK1349572 alone
was nausea (2/24, 8 percent). The most common AE during concomitant therapy
was ocular icterus (11/24, 46 percent). Increased bilirubin was observed only
during concomitant ATV dosing. Co-administration with ATV or ATV/RTV
increased plasma S/GSK1349572 exposure with a more prominent effect from ATV
alone.

Further study is necessary to determine conclusively the efficacy,
safety, and resistance profile of S/GSK1349572. Phase IIb studies of
S/GSK1349572 are currently progressing as planned. ViiV Healthcare expects to
begin the Phase III studies by the end of 2010. S/GSK1349572 was jointly
discovered by Shionogi & Co., Ltd. and GlaxoSmithKline, and is being
developed by ViiV Healthcare and Shionogi & Co., Ltd.

Highlighted Data on SELZENTRY

Several retrospective analyses in both treatment experienced and naïve
patients were presented evaluating additional approaches for determining
tropism and virologic response to maraviroc, including the following:

    - A genotypic analysis of 704 pre-treatment samples from patients in the
      MERIT study who received maraviroc and had a known virologic outcome
      using population-based sequencing of the V3 loop, which identified 11R
      residue as a marker of CXCR4 use.
    - An analysis of data from the MERIT study using population-based
      sequencing of the V3 loop, in which approximately 8 percent of patients
      screened as R5 by the original Trofile(TM) assay were classified as X4
      by V3 sequencing and 193/283 (68 percent) classified as R5 by both the
      enhanced sensitivity Trofile and population-based V3 sequencing had
      week 48 virologic response (<50 copies/mL) on maraviroc.
    - An analysis of data from MERIT, MOTIVATE-1, MOTIVATE-2 and A4001029
      studies using "deep" gp120 V3-loop sequencing, in which deep sequence
      discriminated between responders and non-responders regardless of
      treatment experience and excluded fewer treatment-naïve patients in
      MERIT as non-R5 than the enhanced sensitivity Trofile assay (ESTA)
      while maintaining comparable performance (223/312 (71 percent)) for
      deep sequencing compared to 216/299 (72 percent) for ESTA.
    - An analysis of data from 31 patients with persistent viremia <50
      copies/mL for greater than or equal to 1 year after first line
      antiretroviral treatment initiation (without a CCR5 antagonist)
      comparing the ability of different tropism assays to detect X4 viruses,
      which showed close agreement between V3 quantitative deep sequencing
      and the enhanced sensitivity Trofile assay.

Collectively, these data suggest population-based genotyping may be a
viable alternative to available phenotypic tests in identifying tropism and
predicting response to maraviroc.

SELZENTRY(R) (maraviroc) is a first-in-class oral CCR5 entry inhibitor
approved in the U.S. for both treatment-naïve and treatment-experienced adult
patients with CCR5-tropic HIV-1 virus in combination with other anti-HIV
medicines. SELZENTRY is known as Celsentri(R) outside of the U.S. where it is
indicated for appropriate treatment-experienced patients. Use of SELZENTRY in
patients with dual/mixed or CXCR4-tropic HIV-1 is not recommended. SELZENTRY
will not cure HIV infection.

Indication

SELZENTRY, in combination with other antiretroviral agents, is indicated
for adult patients infected with only CCR5-tropic HIV-1. This indication is
based on analyses of plasma HIV-1 RNA levels in two controlled studies of
SELZENTRY in treatment-experienced patients and one study in treatment-naïve
patients. Both studies in treatment-experienced patients were conducted in
clinically advanced, 3-class antiretroviral-experienced (NRTI, NNRTI, PI, or
enfuvirtide) adults with evidence of HIV-1 replication despite ongoing
antiretroviral therapy. The following points should be considered when
initiating therapy with SELZENTRY:

    - Tropism testing must be conducted with a highly sensitive tropism assay
      that has demonstrated the ability to identify patients appropriate for
      SELZENTRY use
    - Use of SELZENTRY is not recommended in patients with dual/mixed or
      CXCR4-tropic HIV-1 as efficacy was not demonstrated in a Phase 2 study
      of this patient group
    - The safety and efficacy of SELZENTRY have not been established in
      pediatric patients
    - In treatment-naïve patients, more patients treated with SELZENTRY
      experienced virologic failure and developed lamivudine resistance
      compared with efavirenz

Important safety considerations for SELZENTRY

WARNING: See full prescribing information for complete boxed warning.
Hepatotoxicity has been reported which may be preceded by evidence of a
systemic allergic reaction (e.g., pruritic rash, eosinophilia or elevated
IgE). Immediately evaluate patients with signs or symptoms of hepatitis or
allergic reaction.

Liver problems (liver toxicity) have happened in patients taking
SELZENTRY. An allergic reaction may happen before liver problems occur. Stop
taking SELZENTRY and call your doctor right away if you get any of the
following symptoms:

    - An itchy rash on your body (allergic reaction)
    - Your skin or eyes look yellow and/or dark (tea-colored) urine
    - Vomiting and/or upper right stomach area (abdominal) pain

SELZENTRY should always be taken in combination with other medicines used
to treat HIV. SELZENTRY does not cure HIV infection or AIDS (acquired immune
deficiency syndrome). The most serious side effects with SELZENTRY include
liver problems, heart problems (including heart attack), low blood pressure
when standing up, and changes in the immune system. There may also be
possible chance of infection or cancer. In clinical trials, the most common
side effects of SELZENTRY included cough, fever, colds, rash, muscle and
joint pain, stomach pain, and dizziness.

SELZENTRY may affect your immune system, and lead to an increased risk of
getting other infections or cancer. The long-term effects of treatment with
SELZENTRY are unknown at this time. You should also talk to your doctor right
away if you have any of the following other symptoms: nausea, fever, flu-like
symptoms, or fatigue.

If you have side effects when taking SELZENTRY, you should talk to your
doctor right away. When SELZENTRY has been given with other HIV drugs, there
have been serious side effects, including:

    - Liver problems
    - Heart problems, including heart attack
    - Low blood pressure when standing up (postural hypotension). Low blood
      pressure when standing up can cause dizziness or fainting. Do not drive
      a car or operate machinery if you have dizziness while taking SELZENTRY
    - Changes in your immune system. A condition called immune reconstitution
      syndrome can occur when taking HIV medicines. Your immune system could
      get stronger and begin fighting hidden infections in your body such as
      pneumonia, herpes virus, or tuberculosis.

Tell your doctor if you develop new symptoms of infection such as cold
sores, fever, or blisters after starting your HIV medicines.

This is a list of the most common side effects of SELZENTRY:

    - Cough
    - Muscle and joint pain
    - Fever
    - Stomach pain
    - Colds
    - Dizziness
    - Rash

These are not all of the side effects of SELZENTRY. For more information,
ask your doctor or pharmacist. Do not take SELZENTRY if you are allergic to
SELZENTRY or any of its ingredients. Keep your doctor informed about all the
medicines you use, including prescription and nonprescription medicines,
vitamins, and herbal supplements. Do not take products that contain St.
John's Wort (Hypericum perforatum). St. John's Wort may lower the levels of
SELZENTRY in your blood so that it will not work to treat your CCR5-tropic
HIV infection.

SELZENTRY does not cure HIV infection or AIDS, nor does it prevent you
from passing HIV on to others. People taking SELZENTRY may still develop
opportunistic infections or other conditions associated with HIV infection.
The long-term effects of SELZENTRY are not known at this time. For these
reasons it is very important that you remain under a doctor's care.

For additional important information about SELZENTRY, please visit
www.selzentry.com.

Highlighted Data on EPZICOM

Final 96-week results were presented from the AIDS Clinical Trials Group
(ACTG) study A5202, a blinded, randomized equivalence study comparing
abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/FTC)
administered with efavirenz (EFV) or atazanavir/ritonavir (ATZ/RTV).

Final 96-week data for low viral load stratum was presented at this CROI:

    - Data showed that viral failure rates were lower than expected in both
      the ABC/3TC and TDF/FTC arms, and there were no demonstrable
      differences between treatments in time to viral failure in those
      patients with screening <100,000 copies/mL HIV-1 RNA.
    - For the primary safety endpoint (time to first new grade 3/4
      sign/symptom or lab toxicity), safety events occurred sooner for
      ABC/3TC than TDF/FTC with EFV as the 3rd drug but not with ATV/RTV.
    - Regimen changes occurred significantly earlier for ABC/3TC than TDF/FTC
      in the low viral load subgroup, regardless of the third drug used. The
      difference appeared to be the result of an increased frequency of
      hypersensitivity reactions in this group. However, it should be noted
      that this study enrolled subjects prior to the performance of routine
      HLA-B*5701 testing. HLA-B*5701 is a test that identifies those at
      higher risk for developing hypersensitivity reactions.

Previously, a Data Safety Monitoring Board (DSMB) recommended unblinding
those in high viral load stratum (>100,000 copies/mL HIV-1 RNA) due to a
shorter time to viral failure for ABC/3TC than TDF/FTC, although all regimens
effectively reduced the amount of virus in most subjects. Patients were
allowed to continue on their current regimen or shift to another regimen. A
secondary analysis showed the proportion of patients in the high viral load
group with HIV RNA <50 c/mL at week 48 was 75 percent for the arm containing
ABC/3TC and 80 percent for the TDF/FTC arm [(p=0.2), intent-to-treat
analysis, switch included].

Results also were reported from ACTG 5224, a substudy of ACTG 5202
examining the long-term effects of ABC/3TC compared to TDF/FTC, combined with
either EFV or ATV/RTV, on bone mineral density (BMD) and limb fat in HIV
infected treatment-naïve patients. Primary endpoints included DEXA-measured
changes in lumbar spine and hip BMD and the presence of lipoatrophy at 96
weeks. DEXA, or dual X-ray absorptiometry, is a screening tool used to
measure body composition.

Compared to ABC/3TC, TDF/FTC-treated patients had statistically
significant larger declines in lumbar spine and hip BMD. Both ABC/3TC- and
TDF/FTC-based regimens increased limb fat at 96 weeks, with similar
proportion of patients with lipoatrophy. No statistically significant
differences were seen in percent change in limb fat between the NRTI arms by
intent-to-treat or as-treated analyses.

BMD results:

    - At 96 weeks, the mean percent change from baseline in lumbar spine BMD
      was -1.3 percent for ABC/3TC compared to -3.3 percent for TDF/FTC
      (p=0.004). The mean percent change from baseline in hip BMD was -2.6
      percent for ABC/3TC compared to -3.9 percent for TDF/FTC (p=0.025).
    - At 96 weeks, the mean percent change from baseline in lumbar spine BMD
      was -1.7 percent for EFV compared to -3.2 percent for ATV/RTV
      (p=0.035). The mean percent change from baseline in hip BMD was -3.1
      percent for EFV compared to -3.4 percent for ATV/RTV (p=0.59).
    - ATV/RTV led to more significant losses in lumbar spine BMD than EFV.
      Overall, 5.6 percent of subjects had greater than or equal to 1
      fracture (all traumatic), with no significant differences in fracture
      rates between the NRTI arms (p=1.0), or between EFV vs. ATV/RTV arms
      (p=0.29).

EPZICOM (abacavir/lamivudine) is a once-a-day HIV medication that
combines abacavir sulfate and lamivudine in a single tablet and is indicated
for the treatment of HIV-1 infection in adults.

Important Information about EPZICOM

EPZICOM, in combination with other antiretroviral agents, is indicated
for the treatment of HIV-1 infection in adults.

EPZICOM is one of 3 medicines containing abacavir. Before starting
EPZICOM, your healthcare professional will review your medical history in
order to avoid the use of abacavir if you have experienced an allergic
reaction to abacavir in the past.

In one study, more patients had a severe hypersensitivity reaction in the
abacavir once-daily group than in the abacavir twice-daily group.

EPZICOM should not be used as part of a triple-nucleoside regimen.

EPZICOM does not cure HIV infection/AIDS or prevent passing HIV to
others.

Important Safety Information

EPZICOM contains abacavir, which is also contained in ZIAGEN(R) (abacavir
sulfate) and TRIZIVIR(R) (abacavir sulfate, lamivudine, and zidovudine).
Patients taking EPZICOM may have a serious allergic reaction (
hypersensitivity reaction) that can cause death. Your risk of this allergic
reaction is much higher if you have a gene variation called HLA-B*5701 than
if you do not. Your doctor can determine with a blood test if you have this
gene variation. If you get a symptom from 2 or more of the following groups
while taking EPZICOM, call your doctor right away to determine if you should
stop taking this medicine.

If you get a symptom from 2 or more of the following groups while taking
EPZICOM, stop taking EPZICOM and call your doctor right away:

    1. Fever
    2. Rash
    3. Nausea, vomiting, diarrhea, or abdominal (stomach area) pain
    4. Generally ill feeling, extreme tiredness, or achiness
    5. Shortness of breath, cough, or sore throat

Carefully read the Warning Card that your pharmacist gives you and carry
it with you at all times.

If you stop EPZICOM because of an allergic reaction, NEVER take EPZICOM
or any other abacavir-containing medicine (ZIAGEN, TRIZIVIR) again. If you
take EPZICOM or any other abacavir-containing medicine again after you have
had an allergic reaction, WITHIN HOURS you may get life-threatening symptoms
that may include very low blood pressure or death.

If you stop EPZICOM for any other reason, even for a few days, and you
are not allergic to EPZICOM, talk with your healthcare professional before
taking it again. Taking EPZICOM again can cause a serious or life-threatening
reaction, even if you never had an allergic reaction before. If your
healthcare professional tells you that you can take EPZICOM again, start
taking it when you are around medical help or people who can call a doctor if
you need one.

A build-up of lactic acid in the blood and an enlarged liver, including
fatal cases, has been reported.

Do not take EPZICOM if your liver does not function normally.

Some patients infected with both hepatitis B virus (HBV) and HIV have
worsening of hepatitis after stopping lamivudine (a component of EPZICOM).
Discuss any change in treatment with your doctor. If you have both HBV and
HIV and stop treatment with EPZICOM, you should be closely monitored by your
doctor for at least several months.

Worsening of liver disease (sometimes resulting in death) has occurred in
patients infected with both HIV and hepatitis C virus who are taking anti-HIV
medicines and are also being treated for hepatitis C with interferon with or
without ribavirin. If you are taking EPZICOM as well as interferon with or
without ribavirin and you experience side effects, be sure to tell your
doctor.

When you start taking HIV medicines, your immune system may get stronger
and could begin to fight infections that have been hidden in your body, such
as pneumonia, herpes virus, or tuberculosis. If you have new symptoms after
starting your HIV medicines, be sure to tell your doctor.

Changes in body fat may occur in some patients taking antiretroviral
therapy. These changes may include an increased amount of fat in the upper
back and neck ("buffalo hump"), breast, and around the trunk. Loss of fat
from the legs, arms, and face may also occur. The cause and long-term health
effects of these conditions are not known at this time.

Some HIV medicines, including those containing abacavir (ZIAGEN, EPZICOM
or TRIZIVIR), may increase your risk of heart attack. If you have heart
problems, smoke, or suffer from diseases that increase your risk of heart
disease such as high blood pressure, high cholesterol, or diabetes, tell your
doctor.

The most common side effects seen with the drugs in EPZICOM dosed
once-daily were allergic reaction, trouble sleeping, depression, headache,
tiredness, dizziness, nausea, diarrhea, rash, fever, stomach pain, abnormal
dreams, and anxiety. Most of the side effects do not cause people to stop
taking EPZICOM.

For additional important information about EPZICOM please visit
www.epzicom.com.

For additional important information about ZIAGEN please visit
www.treathiv.com

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established by
GlaxoSmithKline (NYSE: GSK) and Pfizer (NYSE: PFE) to deliver advances in
treatment and care for people living with HIV. Our aim is to take a deeper
and broader interest in HIV/AIDS than any company has done before and take a
new approach to deliver effective and new HIV medicines as well as support
communities affected by HIV.

GSK holds an 85 percent interest in the ViiV Healthcare and Pfizer holds
15 percent. GSK and Pfizer announced that they had agreed to form a new
specialist HIV company on April 16, 2009. The transaction was completed on
October 30, 2009. ViiV Healthcare launched on November 3, 2009.

For more information on the company, its management, portfolio, pipeline
and commitment, please visit www.viivhealthcare.com.

Inquiries:

    UK Media inquiries:                  Philip Thomson  +44(020)-8047-5502
                                         Claire Brough   +44(020)-8047-5502

    US Media inquiries:                  Marc Meachem    +1-919-483-5005

    GSK European Analyst/Investor
    inquiries:                           David Mawdsley  +44(020)-8047-5564
                                         Sally Ferguson  +44(020)-8047-5543
                                         Gary Davies     +44(020)-8047-5503

    GSK US Analyst/ Investor inquiries:  Tom Curry       +1-215-751-5419
                                         Jen Hill Baxter +1-215-751-7002

Cautionary statement regarding forward-looking statements

GlaxoSmithKline disclosure notice: Under the safe harbor provisions of
the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions
investors that any forward-looking statements or projections made by GSK,
including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Factors that may affect GSK' s operations are described under
'Risk Factors' in the 'Business Review' in the company' s Annual Report on
Form 20-F for 2008.

Pfizer disclosure notice: Pfizer assumes no obligation to update any
forward-looking statements contained in this release as a result of new
information or future events or developments.

This release contains forward-looking information about Pfizer,
GlaxoSmithKline and ViiV Healthcare and about the prospects of the companies,
including revenues from in-line products and the potential benefits of
product candidates that will be contributed to that company, as well as the
potential financial impact of the transaction. Such information involves
substantial risks and uncertainties including, among other things, decisions
by regulatory authorities regarding whether and when to approve any drug
applications that have been or may be filed for such product candidates as
well as their decisions regarding labeling and other matters that could
affect the availability or commercial potential of such product candidates;
and competitive developments.

A further list and description of risks and uncertainties can be found in
Pfizer's Annual Report of Form 10-K for the fiscal year ended December 31,
2008 and in its reports on Form 10-Q and Form 8-K.

UK Media inquiries, Philip Thomson, +44(020)8047-5502, or Claire Brough, +44(020)8047-5502; US Media inquiries, Marc Meachem, +1-919-483-5005; GSK European Analyst/Investor inquiries, David Mawdsley, +44(20)-8047-5564, Sally Ferguson, +44(20)8047-5543, or Gary Davies, +44(020)8047-5503; GSK US Analyst/ Investor inquiries, Tom Curry, +1-215-751-5419, or Jen Hill Baxter, +1-215-751-7002, all for ViiV Healthcare